lifestyle change and CAD

the american heart association published a position paper focusing on lifestyle interventions to prevent heart disease (see cad lifestyle change circulation 2103 in dropbox, or go to  http://circ.ahajournals.org/content/early/2013/10/07/01.cir.0000435173.25936.e1.citation ).  they note:

    -- there is abundant evidence that the risk of heart disease is much lower in those with better cardiovascular health metrics (nonsmoking, good diet, physical activity, normal BMI, normal BP, optimal lipids and normal fasting glucose): 78% less heart disease over 5.8 years in those with 5 or more of the above compared to those with none, with similar numbers in longer term studies
    --younger adults with healthy behaviors track to having lower biological risk as they age.
    --those with initially poorer health behaviors who can change them do better clinically. 
    --health care providers, even with brief interventions, are able to help patients quit smoking, improve their diets, and increase physical activity. 
    --on a public health scale, these interventions would not only save lots of lives but reduce costs dramatically

but in order to do this:
    --we need to increase the focus on high-value preventive and chronic care and promote healthier behaviors, which requires
            --expanded health care coverage (so people can be part of the health care system)
            --better reimbursement for these interventions (currently, as we know only too well, it is really hard to do this and take care of all the chronic medical problems and all the array of social issues in 15 minutes)  and better reimbursement to primary care would allow for more time with patients.
            --more training for providers in counseling skills (eg motivational interviewing, patient-centered care). 
            --team approach may also help a lot with this, integrating other health professionals, as well as interfacing with commmunity resources to reinforce the message and provide concrete support (biking trails, farmers' markets...)

so, all in all, i think this represents a good call-to-action to prevent heart disease (and lots of other diseases as well, but this is from the am heart assn) which focuses on both the specific clinical interaction between the provider and patient and the more global public health imperat

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

cystatin c: better predictor of bad outcomes than creatinine

  another article found significant discordance between creatinine and cystatin C in assessing renal function,  finding that the latter correlated most strongly with both renal and non-renal adverse clinical outcomes (see   ckd cystatin c better than creat AJKD2023  in  dropbox or doi: 10.1053/ j.ajkd.2023.04.002)   Details: -- 158,601 adults who were in the Stockholm Creatinine Measurements (SCREAM) project and had testing of creatinine and cystatin C on the same day during a healthcare encounter, from 2010-2018     -- >400,000 outpatient tests were done for both creatinine and cystatin C levels -- mean age 62, 48% female -- mean eGFR by creatinine (   eGFR cr ) 80; mean eGFR by cystatin C ( eGFR cys  ) 73 -- mean stage of renal insufficiency: 39%  eGFR cr   90+; 38%  eGFR cr  60-89; 12%  eGFR cr  45-59; 7.1%  eGFR cr  30-44; 3.2%  eGFR cr  15-29, 0.7%  eGFR cr ...
Read more

diabetes DPP-4 inhibitors and the risk of heart failure

the FDA just came out with a safety alert about 2 DPP-4 inhibitors and the increased risk of heart failure (released 04/05/2016)(see  http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery ​ ). details: --saxagliptin and alogliptin were singled out because of 2 clinical trials in diabetic patients with heart disease. in each trial more patients taking these meds were hospitalized for heart failure vs those on placebo     --in the saxagliptin trial: 3.5% were hospitalized for heart failure (vs 2.8% on placebo). risk factors included prior heart failure or kidney disease     --in the alogliptin trial: 3.9% were hospitalized for heart failure (vs 3.3% on placebo) --recommendation by the FDA:     -- we should consider stopping these drugs if the patient develops heart failure ...
Read more

UPDATE: ASCVD risk factor critique

I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the current ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:          ...
Read more